# US 2025/0082740 A1 · Use of cxcl14

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082740 A1
- Document ID: US20250082740A1
- Status: Published application
- Kind: A1
- Application number: 18/721,511
- Filed: 2022-06-06
- Published: 2025-03-13
- Earliest claimed: 2022-01-24
- Assignees: Newish Technology (Beijing) Co., Ltd.
- Applicants: Newish Technology (Beijing) Co., Ltd.
- Inventors: Hailong QI; Xudong WANG; Jiandong JIANG; Lulu WANG; Defang LIU; Yanling YAO; Xiaofang WANG; Zhongjie SUN
- Web page: https://patentgrep.com/patent/US20250082740A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0011: {Cancer antigens}
- A61K 39/001142: {Chemokines}
- A61K 39/12: Viral antigens
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/521: {Chemokines}
- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/625: {containing a sequence coding for a signal sequence}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/575: {humoral response}
- C07K 2319/02: containing a signal sequence
- C07K 2319/43: containing a FLAG-tag
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure relates to the field of molecular biology, and in particular relates to the use of CXCL 14. According to the present invention, different antigen proteins are transferred to the surface of a DC cell by means of the chemotactic binding capacity of CXCL 14 and surface receptors of immune cells such as DC cells. A chemokine of CXCL14 can effectively induce the binding of an antigen molecule to a specific immune cell at the N-terminal of an antigen protein, such that the cross presentation effect of the antigen molecule is greatly enhanced, and CXCL14 can finally induce a stronger specific immune response of the antigen molecule.

## Claims

### Claim 1

A method for improving antigen presentation effect, comprising administering to a subject in need thereof at least one of I)-VI), wherein
I) a T2 fragment with an amino acid sequence set forth in SEQ ID NO: 4;
II) chemokine CXCL14;
III) a fragment being more than 80% homologous with and functionally identical or similar to I) or II);
IV) a nucleic acid molecule encoding I) or II);
V) a nucleic acid molecule that is derived from the nucleotide sequence of the nucleic acid molecule in IV) by deletion, addition or substitution of one or more nucleotides and encode a protein functionally identical or similar to the nucleic acid molecule in IV); and
VI) a nucleic acid molecule fully or partially complementary to V).

### Claim 2

A fusion protein, comprising CXCL14 and an antigen or comprising CXCL14, an antigen and a T2 fragment.

### Claim 3 (depends on 2)

The fusion protein according to claim 2, from N-terminal to C-terminal, sequentially comprising an IgE signal peptide, CXCL14, a linker, the antigen and the T2 fragment.

### Claim 4 (depends on 2)

The fusion protein according to claim 2, wherein the antigen is derived from a virus, pathogenic microbe and/or tumor;
the virus is selected from the group consisting of HPV, EBV, HCV, HIV, HBV, VZV, a coronavirus, and a combination thereof; and
the tumor is selected from the group consisting of liver cancer, cervical cancer, ovarian cancer, lung cancer, head and neck cancer, prostate cancer, breast cancer, blood cancer, ovarian cancer, colorectal cancer, and a combination thereof.

### Claim 5 (depends on 2)

A nucleic acid molecule encoding the fusion protein according to claim 2.

### Claim 6 (depends on 5)

A nucleic acid fragment comprising the nucleic acid molecule according to claim 5, 5′-UTR, 3′-UTR and 3′-end polyA.

### Claim 7 (depends on 5)

An expression vector comprising a vector backbone and the nucleic acid molecule according to claim 5.

### Claim 8 (depends on 7)

A host transformed or transfected with the expression vector according to claim 7.

### Claim 9 (depends on 2)

A method for producing the fusion protein according to claim 2, comprising culturing a host transformed or transfected with an expression vector comprising a vector backbone and a nucleic acid encoding the fusion protein and collecting a culture containing the fusion protein.

### Claim 10

(canceled)

### Claim 11 (depends on 2)

A product for preventing and/or treating a disease, comprising the fusion protein according to claim 2.

### Claim 12 (depends on 11)

A method for preventing and/or treating a disease, comprising administering to a subject in need thereof the product according to claim 11.
